Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.94 USD | +3.94% | +11.94% | -44.01% |
08/05 | Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating | MT |
08/05 | Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.01% | 67Cr | |
+31.37% | 60TCr | |
-2.60% | 37TCr | |
+20.83% | 33TCr | |
+5.69% | 29TCr | |
+14.83% | 24TCr | |
+9.93% | 21TCr | |
-6.95% | 20TCr | |
+10.77% | 17TCr | |
+0.10% | 16TCr |
- Stock Market
- Equities
- EYPT Stock
- News EyePoint Pharmaceuticals, Inc.
- Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating